Ken Griffin Bei Gene, Ltd. Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$143.93 - $224.51 $345,432 - $538,824	-2,400 Reduced 61.54%	1,500 $336,000
Q2 2024 Aug 14, 2024	BUY	$129.52 - $174.32 $220,184 - $296,344	1,700 Added 77.27%	3,900 $556,000
Q1 2024 May 15, 2024	SELL	$141.8 - $181.47 $864,980 - $1.11 Million	-6,100 Reduced 73.49%	2,200 $344,000
Q4 2023 Feb 14, 2024	SELL	$158.67 - $201.58 $1.09 Million - $1.39 Million	-6,900 Reduced 45.39%	8,300 $1.5 Million
Q3 2023 Nov 14, 2023	BUY	$179.87 - $225.13 $791,428 - $990,572	4,400 Added 40.74%	15,200 $2.73 Million
Q2 2023 Aug 14, 2023	BUY	$178.3 - $266.78 $570,560 - $853,695	3,200 Added 42.11%	10,800 $1.93 Million
Q1 2023 May 15, 2023	SELL	$215.53 - $274.5 $2.84 Million - $3.62 Million	-13,200 Reduced 63.46%	7,600 $1.64 Million
Q4 2022 Feb 14, 2023	BUY	$125.51 - $229.3 $1.42 Million - $2.59 Million	11,300 Added 118.95%	20,800 $4.57 Million
Q3 2022 Nov 14, 2022	BUY	$131.8 - $202.24 $645,820 - $990,976	4,900 Added 106.52%	9,500 $1.28 Million

249

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $19.6B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.